
|Videos|April 25, 2017
Recurrent Colon Cancer with Liver Metastases
Recurrent Colon Cancer with Liver Metastases
Advertisement
November 2012
- A 51-year-old man was referred to gastroenterology for screening colonoscopy.
- Family history includes pancreatic cancer on his father’s side and pre-menopausal breast cancer in his aunt.
- Colonoscopy revealed a 3-cm mass, proximal to the hepatic flexure.
- Biopsy confirmed the lesion to be of adenocarcinoma histology.
- At the time, the patient underwent right hemicolectomy revealing a moderately differentiated tumor. Fifteen lymph nodes were removed and tested negative for metastatic disease, denoting stage T3N0M0 colon cancer.
- The patient healed without complications and received no further treatment.
April 2015
- The patient continued to feel well, except for occasional fatigue and diarrhea.
- Routine evaluation showed elevated carcinoembryonic antigen.
- PET/CT scan revealed several small lesions in multiple lobes of the liver that were PET avid
- Biopsy was performed and confirmed the liver lesions to be metastases from colon cancer
- The patient was referred to a local oncologist and started on infusional 5-FU and oxaliplatin (FOLFOX) in combination with bevacizumab.
- CT scan 2 months after starting treatment showed a partial response to therapy; at 4 months the patients tumor continued to shrink
- Oxaliplatin was discontinued; subsequently the patient received maintenance therapy with capecitabine and bevacizumab, resulting in continued disease control
February 27, 2017
- The patient has had stable disease for 22 months and remains on bevacizumab maintenance therapy.
- He appears generally well and free of symptoms.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































